



Cover: Mucus-secreting goblet cells (green) in a crypt of Lieberkuhn, a large pit in the intestinal wall. Stephanie Schuller/Science Photo Library.

Journal of the British Society of Gastroenterology

Impact Factor: 9.76

Editor

Professor Robin C Spiller (UK)

Deputy Editor

Severine Vermeire (Belgium)

Associate Editors

- Ramon Bataller (Spain)
- Guy Boeckxstaens (Belgium)
- Laurence Egan (Ireland)
- Alexander Gerbes (Germany)
- William Grady (USA)
- Thomas Gress (Germany)
- Ernst Kuipers (The Netherlands)
- David Mutimer (UK)
- Herbert Tilg (Austria)

Editorial Office

Gut
 BMJ Journals
 BMA House, Tavistock Square
 London, WC1H 9JR, UK
 T: +44 (0)20 7383 6394
 F: +44 (0)20 7383 6668
 E: guteditorial@bmjgroup.com
 ISSN: 0017-5749 (print)
 ISSN: 1468-3288 (online)

Disclaimer: *Gut* is owned and published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association and the British Society of Gastroenterology. The owners grant editorial freedom to the Editor of *Gut*. *Gut* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Gut is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the British Society of Gastroenterology or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of *Gut* or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright © 2010 BMJ Publishing Group and British Society of Gastroenterology. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior permission

Gut is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Latimer Trend & Co Ltd, Plymouth, UK

Gut (ISSN 0017-5749) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ. POSTMASTER: send address changes to *Gut*, Mercury International Ltd, 365 Blair Road, Avenel, NJ, 07001, USA.

Leader

- 1** Tailoring the length of antiviral treatment for hepatitis C
A Mangia, A Andriulli

Commentaries

- 6** B cells, IgE and mechanisms of type I hypersensitivity in eosinophilic oesophagitis
D J Mulder, C J Justinich
- 7** Predicting the response to infliximab from trough serum levels
P Rutgeerts, S Vermeire, G Van Assche
- 9** Screening for colorectal cancer: flexible sigmoidoscopy and faecal occult blood immunochemical testing. Which test is superior?
G Castiglione
- 10** Optimum use of diuretics in managing ascites in patients with cirrhosis
M Bernardi

Oesophagus

- 12** Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis
M Vicario, C Blanchard, K F Stringer, M H Collins, M K Mingler, A Ahrens, P E Putnam, J P Abonia, J Santos, M E Rothenberg
- 21** Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
A Straumann, S Conus, P Grzonka, H Kita, G Kephart, C Bussmann, C Beglinger, D A Smith, J Patel, M Byrne, H-U Simon
- 31** Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
N Pandeya, P M Webb, S Sadeghi, A C Green, D C Whiteman, for the Australian Cancer Study

Oesophageal and gastric cancer

- 39** Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study
J Stevens, L J Schouten, R A Goldbohm, P A van den Brandt

Inflammatory bowel disease

- 49** Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C H Seow, A Newman, S P Irwin, A H Steinhart, M S Silverberg, G R Greenberg

Neurogastroenterology

- 55** Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with 1 year follow-up
A Frudinger, D Kölle, W Schwaiger, J Pfeifer, J Paede, S Halligan

Colon cancer

- 62** Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy
L Hol, M E van Leerdam, M van Ballegooijen, A J van Vuuren, H van Dekken, J C I Y Reijerink, A C M van der Togt, J D F Habbema, E J Kuipers
- 69** Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer
G Kijanka, S Hector, E W Kay, F Murray, R Cummins, D Murphy, B D MacCraith, J H M Prehn, D Kenny

Hepatology

- 79** Haematopoietic stem cell recruitment to injured murine liver sinusoids depends on $\alpha_4\beta_1$ integrin/VCAM-1 interactions
D P J Kavanagh, L E Durant, H A Crosby, P F Lalor, J Frampton, D H Adams, N Kalia

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://gut.bmj.com/info/unlocked.dtl>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
www.publicationethics.org.uk



- 88** Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens

J G Fox, Y Feng, E J Theve, A R Raczynski, J L A Fiala, A L Doernte, M Williams, J L McFaline, J M Essigmann, D B Schauer, S R Tannenbaum, P C Dedon, S A Weinman, S M Lemon, R C Fry, A B Rogers

Cirrhosis

- 98** Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial

P Angeli, S Fasolato, E Mazza, L Okolicsanyi, G Maresio, E Velo, A Galioto, F Salinas, M D'Aquino, A Sticca, A Gatta

- 105** Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites

A Krag, F Bendtsen, J H Henriksen, S Møller

JournalScan

- 112** Edited by G Aithal

Recent advances in basic science

- 115** Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels?

A M Woltman, A Boonstra, H L A Janssen

- 126** TRP channels: new targets for visceral pain

L A Blackshaw, S M Brierley, P A Hughes

PostScript

- 137** Letters

- 140** Correction


Editor's quiz

- 5** Transfusion-refractory anaemia in liver cirrhosis

J C C So, Y-Y Hwang, W-H Shek, C C K Lam, C-L Lai, Y-L Kwong

- 111** A case of idiopathic portal vein thrombosis?

R D Johnston, C Chang, R K Singh, A Austin



Easily digestible research every month

Gut is the premier gastroenterology journal in Europe with an impressive impact factor of 9.76, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for **just £194 a year** (€262, \$378). Too much paper on your desk already? An online subscription is **just £106** (€143, \$207).

Visit group.bmj.com/group/subs-sales - your subscription to this first class journal is just a few clicks away.

gut.bmj.com

BMJ Journals